论文部分内容阅读
膀胱肿瘤单纯手术治疗后复发率高,5年复发率可达60％-90％,目前一般均采用术后辅以膀胱内药物化疗或免疫治疗以预防术后复发,疗效仍不理想,且可能出现较为严重的并发症。我们从92年底开始应用自体LAK细胞合并人天然白细胞介素Ⅱ(nIL2)行膀胱粘膜下注射预防浅表膀胱癌术后复发,近期疗效满意。 本组病例9例,男8例,女1例,年龄40—69岁,均经病理证实为移行细胞癌,其中1级2例,Ⅱ级5例,Ⅱ—Ⅲ级2例。其2例为复发肿瘤。T_1期5例,T_2期4例。3例为膀胱多发肿瘤。分别行膀胱部分切除或膀胱肿瘤切除。 无菌条件下抽取患者外周血,常规分离淋巴细胞,用含有5％的人AB型血清,4Iu胰岛素/ml和25ug/mLPHA的RPMI1640混悬液使细胞浓度为2×10~6/mL,加nIL2 40u/mL诱导6—8天,洗涤细胞备用,使用药检测其活性及其数量,加入nIL2 8000~u,5％GNS20—30ml,LAK细胞数量2—5×10~8个,术中切除膀胱肿瘤后,
Bladder cancer after simple surgical treatment of recurrence rate, 5-year recurrence rate of up to 60% -90%, are generally used after surgery with intravesical chemotherapy or immunotherapy to prevent postoperative recurrence, the effect is still not ideal, and may A more serious complications. We started from the end of 92 application of autologous LAK cells combined with human interleukin Ⅱ (nIL2) bladder submucosal injections to prevent postoperative recurrence of superficial bladder cancer, the recent satisfactory results. The group of 9 patients, 8 males and 1 female, aged 40-69 years old, were pathologically confirmed as transitional cell carcinoma, including 2 cases of grade 1, grade Ⅱ in 5 cases, Ⅱ-Ⅲ grade in 2 cases. The two cases of recurrent tumors. T_1 in 5 cases, T_2 in 4 cases. 3 cases of bladder multiple tumors. Partial bladder resection or bladder tumor resection. Peripheral blood samples were taken from patients under sterile conditions. Lymphocytes were routinely isolated and the cell concentration was 2 × 10 ~ 6 / mL with RPMI1640 suspension containing 5% human AB serum, 4Iu insulin / ml and 25ug / mL PHA nIL2 40u / mL induction 6-8 days, the cells were washed and used to measure the activity and its quantity, adding nIL2 8000 ~ u, 5% GNS20-30ml, LAK cell number 2-5 × 10 ~ 8, resection After bladder cancer,